PerpEquitiesEquity
Illumina, Inc. (ILMN) perpetual futures
Illumina provides sequencing and array technologies for genetic and genomic analysis, serving research, clinical, pharmaceutical, and consumer genomics customers worldwide.
-0.3%NASDAQ closed
Price chart
Interactive TradingView chart
TradingView symbol NASDAQ:ILMN
Loads TradingView's third-party widget (about 1 MB) on demand.
Auto: underlying reference priceOpen in TradingView
Trading data
Perpetual market activity
0/1 live markets
Trading data
Perpetual market activity
Venues
1
Live markets
0/1
24h volume
-
Open interest
-
Best liquidity
-
Tightest spread
-
Highest volume
-
Settlement mix
USDT · 1/1
Perp/spot vol.
-
OI / float
-
Spot performance
1D-0.33%
5D+2.13%
1M+8.85%
6M+92.09%
YTD+82.08%
1Y+135.31%
BingXBest venues for this underlying
Best liquidity
-No live data-
Tightest spread
-No live data-
Highest volume
-No live data-
Company data
Company fundamentals
Updated 1h ago
Company data
Company fundamentals
Market cap
$36.1B
Updated 1h ago
Revenue
$4.5B
Trailing 12 months
Revenue growth
+7%
Next fiscal year
Profit margin
+18.4%
P/E
44.1
Peer P/E 18.6
Free cash flow
$939M
Trailing 12 months
More metrics
Net income
$825M
Trailing 12 months
P/S
8.0
Peer P/E
18.6
Similar listed perps
Revenue estimate
$4.6B
Next fiscal year
Earnings
2026-10-29
Revenue est. $1.2B · Updated 1h ago
Dividend
-
Fundamental detail
Annual + quarterlyLatest revenue$4.3B
Net margin+19.6%
Free cash flow$931M
Net debt$1.1B
PeriodRevenueGrowthNet incomeFCF
2020$3.2B-9%$656M$891M
2021$4.5B+40%$762M$337M
2022$4.6B+1%-$4.4B$106M
2023$4.5B-2%-$1.2B$282M
2024$4.4B-3%-$1.2B$709M
2025$4.3B-1%$850M$931M
PeriodGross marginOperating marginNet marginROEROA
2020+68.0%+17.9%+20.3%+14.0%+8.6%
2021+69.7%-2.7%+16.8%+7.1%+5.0%
2022+64.8%-91.2%-96.1%-66.7%-35.9%
2023+60.9%-23.7%-25.8%-20.2%-11.5%
2024+65.4%-19.1%-28.0%-51.5%-19.4%
2025+66.7%+19.9%+19.6%+31.2%+12.8%
PeriodCashDebtNet debtCurrent ratio
2020$1.8B$1.9B$96M3.60
2021$1.2B$2.5B$1.3B2.48
2022$2B$3.6B$1.5B1.28
2023$1B$2.3B$1.2B1.66
2024$1.1B$2.6B$1.5B1.78
2025$1.4B$2.6B$1.1B2.08
PeriodMarket capEnterprise valueP/SP/E
2020$52.5B$52.6B16.280.1
2021$55.5B$56.8B12.372.9
2022$30.9B$32.4B6.7-7.0
2023$21.4B$22.6B4.7-18.4
2024$21.2B$22.7B4.9-17.4
2025$20.8B$22B4.824.5
PeriodRevenueGrowthNet incomeFCF
Q3 2024$1.1B-3%$705M$284M
Q4 2024$1.1B-2%$187M$335M
Q1 2025$1B-3%$131M$201M
Q2 2025$1.1B-5%$235M$211M
Q3 2025$1.1B0%$150M$260M
Q4 2025$1.2B+5%$334M$267M
Q1 2026$1.1B+5%$134M$251M
Q2 2026$1.2B+10%$207M$161M
PeriodGross marginOperating marginNet marginROEROA
Q3 2024+69.0%+68.6%+65.3%+33.2%+11.7%
Q4 2024+65.9%+18.3%+16.9%+7.9%+3.0%
Q1 2025+65.8%+17.7%+12.6%+5.5%+2.1%
Q2 2025+67.8%+21.0%+22.2%+10.4%+3.9%
Q3 2025+67.6%+21.3%+13.9%+6.3%+2.4%
Q4 2025+67.1%+22.2%+28.8%+12.3%+5.0%
Q1 2026+66.1%+19.2%+12.3%+5.0%+2.0%
Q2 2026+66.4%+21.1%+17.9%+7.3%+3.1%
PeriodCashDebtNet debtCurrent ratio
Q3 2024$869M$2.7B$1.8B2.43
Q4 2024$1.1B$2.6B$1.5B1.78
Q1 2025$1.1B$2.6B$1.5B1.86
Q2 2025$934M$2.6B$1.7B1.81
Q3 2025$1.1B$2.6B$1.5B1.43
Q4 2025$1.4B$2.6B$1.1B2.08
Q1 2026$1.1B$2.5B$1.5B1.75
Q2 2026$1B$2.5B$1.5B1.80
PeriodMarket capEnterprise valueP/SP/E
Q3 2024$20.7B$22.5B19.27.4
Q4 2024$21.2B$22.7B19.228.3
Q1 2025$12.6B$14.1B12.124.2
Q2 2025$15B$16.6B14.215.9
Q3 2025$14.1B$15.6B13.023.4
Q4 2025$20.6B$21.7B17.715.4
Q1 2026$18.5B$19.9B16.934.3
Q2 2026$27.3B$28.8B23.633.0
Refreshed 1h ago
Charts: revenue, profit, cash flow & valuation
CashDebt
Gross marginOperating marginNet margin
P/EP/S
CashDebt
Gross marginOperating marginNet margin
P/EP/S
Next catalyst
Catalysts
Next catalyst
Catalysts
Earnings
2026-10-29
Revenue est. $1.2B · Updated 1h ago
No unusual perp activity right now.
Research data
Analysts, filings and peer context
Research data
Analysts, filings and peer context
Estimates
6DateEPS estimateRevenue estimateGrowthAnalysts
FY 20265.35$4.6B+7%12
FY 20276.08$4.9B+13%12
FY 20287.02$5.3B+21%7
FY 20298.07$5.7B+32%4
FY 20308.96$6B+38%2
Q1 20271.32$1.2B+6%4
Company events
62026-10-29EarningsActual - / Estimate 1.36-
2026-07-30EarningsActual 1.31 / Estimate 1.23Beat
2026-04-30EarningsActual 1.15 / Estimate 1.05Beat
2026-02-05EarningsActual 1.35 / Estimate 1.24Beat
2025-10-30EarningsActual 1.34 / Estimate 1.17Beat
2025-07-31EarningsActual 1.19 / Estimate 1.02Beat
Peer comparison
Similar listed perpsRevenue mix
PendingSegment data is not available yet.
Analysts
PendingNo analyst data available yet.
Ownership
ILMN-PERPOwnership data is being populated.
Filings
PendingNo filings available yet.
Transcripts
PendingNo transcripts available yet.
Latest updates
No recent updates available.No recent updates available.
Analyst track record
How the analysts covering ILMN have done: ratings, price-target accuracy and the measured reaction after their calls.
| 12 months | 3 years | |
|---|---|---|
| Ratings | 107 | 406 |
| Analysts | 21 | 30 |
| Buy / hold / sell | 42 / 38 / 27 | 189 / 147 / 70 |
| Upgrades / downgrades / initiations | 4 / 1 / 2 | 12 / 12 / 6 |
| Price targets hit / missed | 103 / 2 (98%) | 355 / 26 (93%) |
| Avg. return after a rating (TipRanks) | +78.3% | +80.6% |
| Best / worst call | +489.7% / -8.2% | +489.7% / -24.9% |
After buy calls on this stock: not enough measured cases yet
Latest ratings
| Date | Analyst | Call | Target | |
|---|---|---|---|---|
| Sep 15, 2026 | Daniel AriasStifel Nicolaus | BuyMaintained | $225 | article ↗ |
| Sep 11, 2026 | Kyle Mikson CFACanaccord Genuity | HoldReiterated | – | article ↗ |
| Sep 9, 2026 | Doug SchenkelUBS | BuyUpgraded | $260 | article ↗ |
| Sep 9, 2026 | Unknown AnalystUBS | BuyUpgraded | $260 | article ↗ |
| Sep 9, 2026 | Eve BursteinBernstein | HoldMaintained | $215 | article ↗ |
TipRanks data via FMP · computed Sep 22, 2026 · 107 ratings
Embed this asset
<a href="https://perpequities.com/stocks/ilmn-perp"><img src="https://perpequities.com/badge/ilmn-perp.svg" width="240" height="64" alt="ILMN perpetuals · perpequities.com" loading="lazy"></a>